Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure

被引：0
|
作者：
Bin Lee, Yun [1 ]
Lee, Cheol-Hyung [1 ]
Kim, Minseok Albert [1 ]
Jang, Heejoon [1 ]
Oh, Hyunwoo [1 ]
Kim, Sun Woong [1 ]
Cho, Eun Ju [1 ]
Lee, Kyung-Hun [2 ,3 ]
Lee, Jeonghoon [1 ]
Yu, Su Jong [1 ]
Yoon, Jung-Hwan [1 ]
Kim, Tae-You [2 ,3 ]
Kim., Yoon Jun [1 ]
机构：
[1] Seoul Natl Univ Coll Med, Dept Internal Med & Liver Res Inst, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT519
引用
收藏
页码：S913 / S914
页数：2
相关论文
共 50 条
  • [21] REGORAFENIB FOR TAIWANESE PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA THAT PROGRESSED ON SORAFENIB TREATMENT
    Hsu, Po-Yao
    Cheng, Tzu-Sheng
    Liang, Po-Cheng
    Hsu, Cheng-Ting
    Wei, Yu-Ju
    Jang, Tyng-Yuan
    Yeh, Ming-Lun
    Huang, Ching-I
    Lin, Yi-Hung
    Wang, Chih-Wen
    Hsieh, Ming-Yen
    Hou, Nai-Jen
    Hsieh, Meng-Hsuan
    Dai, Chia-Yen
    Lin, Zu-Yau
    Chen, Shinn-Chern
    Huang, Jee-Fu
    Chuang, Wan-Long
    Huang, Chung-Feng
    Yu, Ming-Lung
    HEPATOLOGY, 2021, 74 : 666A - 667A
  • [22] Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takata, Noboru
    Takeda, Yasuhito
    Kido, Hidenori
    Iida, Noriho
    Kitahara, Masaaki
    Shimakami, Tetsuro
    Takatori, Hajime
    Arai, Kuniaki
    Kawaguchi, Kazunori
    Kitamura, Kazuya
    Yamashita, Taro
    Sakai, Yoshio
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY RESEARCH, 2021, 51 (02) : 190 - 200
  • [23] Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma progressing on sorafenib treatment
    Hsu, Po-Yao
    Cheng, Tzu-Sheng
    Liang, Po-Cheng
    Hsu, Cheng-Ting
    Jang, Tyng-Yuan
    Yeh, Ming-Lun
    Huang, Ching-I
    Dai, Chia-Yen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Huang, Jee-Fu
    Chuang, Wan-Long
    Huang, Chung-Feng
    Yu, Ming-Lung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 114 - 114
  • [24] Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
    Xu, Yongkang
    Fu, Shumin
    Liu, Kan
    Mao, Ye
    Wu, Jianbing
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 853 - 863
  • [25] EFFECTIVENESS OF LENVATINIB VERSUS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATIC DECOMPENSATION
    Park, Min Kyung
    Lee, Yun Bin
    Moon, Hyemi
    Choi, Na Ryung
    Kim, Minseok Albert
    Nam, Joon Yeul
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    HEPATOLOGY, 2021, 74 : 637A - 637A
  • [26] Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation
    Park, Min Kyung
    Lee, Yun Bin
    Moon, Hyemi
    Choi, Na Ryung
    Kim, Minseok Albert
    Jang, Heejoon
    Nam, Joon Yeul
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (10) : 4939 - 4949
  • [27] Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation
    Min Kyung Park
    Yun Bin Lee
    Hyemi Moon
    Na Ryung Choi
    Minseok Albert Kim
    Heejoon Jang
    Joon Yeul Nam
    Eun Ju Cho
    Jeong-Hoon Lee
    Su Jong Yu
    Yoon Jun Kim
    Jung-Hwan Yoon
    Digestive Diseases and Sciences, 2022, 67 : 4939 - 4949
  • [28] Sorafenib Associated Survival in Treatment Naive Versus Treatment Experienced Patients With Advanced Hepatocellular Carcinoma
    Devlin, Paulina
    Cheng, Shanna
    Vyas, Rahul
    Parikh, Neehar D.
    GASTROENTEROLOGY, 2016, 150 (04) : S516 - S516
  • [29] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345